STEM CELLS USED FOR AGE-RELATED MACULAR DEGENERATION
Dr Jenna Hall
Senior Research Associate
University of Melbourne, Victoria, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | January 2025
Dr. Jenna Hall is a passionate and accomplished biologist with expertise in induced pluripotent stem cell (iPSC) culture, disease modelling, and high-throughput automated systems. She recently earned her PhD from the University of Melbourne, where her research focused on using iPSC-derived retinal pigment epithelium (RPE) cells to study age-related macular degeneration. Dr Hall’s technical skillset spans manual and automated cell reprogramming and differentiation, quantitative microscopy-based phenotyping, and large scale -omics analysis.
Dr Hall was awarded a highly competitive and sought after Australian Research Council Centre for Personalised Therapeutics and Technologies (ARC CPTT) scholarship which, in addition to funding her PhD, included an industry internship with a leading life sciences consultancy firm. Her internship with Biointelect allowed her to contribute to strategic projects addressing key challenges in Australia’s biotechnology ecosystem. Her white papers on the country’s vaccine and drug value chain, as well as anti-obesity medication, demonstrated her ability to combine scientific knowledge with commercial insights to influence policy and improve pandemic preparedness.
Dr Hall has over four years of industry experience, including her time at the New York Stem Cell Foundation, where she collaborated with engineers and data scientists to develop scalable workflows for cell reprogramming, downstream differentiation, and automated maintenance. For her next career step, Dr Hall is hoping to secure a role in a fertility research lab.
You Might also like
-
Dr Nischal Sahai
RESEARCH IN BRAIN COMPUTER INTERFACE
@ SYNCHRON
MELBOURNE, VICTORIA, AUSTRALIA -
Dr Venkata Tarigoppula
RESEARCH IN BRAIN COMPUTER INTERFACE
@ SYNCHRON
MELBOURNE, VICTORIA, AUSTRALIA -
Pancreatic and lung cancers driven by mutations in the cancer gene KRAS
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors).